ZEAL.CO vs. NOVO-B.CO
Compare and contrast key facts about Zealand Pharma A/S (ZEAL.CO) and Novo Nordisk A/S (NOVO-B.CO).
Performance
ZEAL.CO vs. NOVO-B.CO - Performance Comparison
Loading graphics...
ZEAL.CO vs. NOVO-B.CO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ZEAL.CO Zealand Pharma A/S | -36.11% | -34.81% | 91.72% | 85.30% | 38.80% | -34.22% | -6.29% | 185.68% | -3.06% | -20.19% |
NOVO-B.CO Novo Nordisk A/S | -24.65% | -46.40% | -9.59% | 50.74% | 29.53% | 75.62% | 12.77% | 32.92% | -8.60% | 35.35% |
Returns By Period
In the year-to-date period, ZEAL.CO achieves a -36.11% return, which is significantly lower than NOVO-B.CO's -24.65% return. Over the past 10 years, ZEAL.CO has outperformed NOVO-B.CO with an annualized return of 8.57%, while NOVO-B.CO has yielded a comparatively lower 5.27% annualized return.
ZEAL.CO
- 1D
- 1.02%
- 1M
- -18.87%
- YTD
- -36.11%
- 6M
- -39.80%
- 1Y
- -36.02%
- 3Y*
- 11.53%
- 5Y*
- 8.24%
- 10Y*
- 8.57%
NOVO-B.CO
- 1D
- 2.60%
- 1M
- 3.38%
- YTD
- -24.65%
- 6M
- -33.14%
- 1Y
- -48.24%
- 3Y*
- -22.16%
- 5Y*
- 4.16%
- 10Y*
- 5.27%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ZEAL.CO vs. NOVO-B.CO — Risk / Return Rank
ZEAL.CO
NOVO-B.CO
ZEAL.CO vs. NOVO-B.CO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Zealand Pharma A/S (ZEAL.CO) and Novo Nordisk A/S (NOVO-B.CO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ZEAL.CO | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.55 | -0.88 | +0.32 |
Sortino ratioReturn per unit of downside risk | -0.40 | -1.12 | +0.72 |
Omega ratioGain probability vs. loss probability | 0.94 | 0.84 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | -0.77 | -0.87 | +0.10 |
Martin ratioReturn relative to average drawdown | -1.65 | -1.48 | -0.17 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| ZEAL.CO | NOVO-B.CO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.55 | -0.88 | +0.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | 0.11 | +0.03 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.17 | 0.16 | 0.00 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.18 | 0.51 | -0.33 |
Correlation
The correlation between ZEAL.CO and NOVO-B.CO is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
ZEAL.CO vs. NOVO-B.CO - Dividend Comparison
ZEAL.CO has not paid dividends to shareholders, while NOVO-B.CO's dividend yield for the trailing twelve months is around 4.94%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ZEAL.CO Zealand Pharma A/S | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NOVO-B.CO Novo Nordisk A/S | 4.94% | 3.58% | 1.59% | 1.01% | 1.19% | 1.27% | 2.02% | 2.11% | 2.64% | 2.27% | 3.69% | 1.25% |
Drawdowns
ZEAL.CO vs. NOVO-B.CO - Drawdown Comparison
The maximum ZEAL.CO drawdown since its inception was -75.53%, roughly equal to the maximum NOVO-B.CO drawdown of -76.75%. Use the drawdown chart below to compare losses from any high point for ZEAL.CO and NOVO-B.CO.
Loading graphics...
Drawdown Indicators
| ZEAL.CO | NOVO-B.CO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.53% | -76.75% | +1.22% |
Max Drawdown (1Y)Largest decline over 1 year | -56.96% | -54.94% | -2.02% |
Max Drawdown (5Y)Largest decline over 5 years | -75.38% | -76.75% | +1.37% |
Max Drawdown (10Y)Largest decline over 10 years | -75.53% | -76.75% | +1.22% |
Current DrawdownCurrent decline from peak | -68.76% | -75.38% | +6.62% |
Average DrawdownAverage peak-to-trough decline | -29.52% | -15.80% | -13.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.76% | 32.14% | -5.38% |
Volatility
ZEAL.CO vs. NOVO-B.CO - Volatility Comparison
Zealand Pharma A/S (ZEAL.CO) has a higher volatility of 48.77% compared to Novo Nordisk A/S (NOVO-B.CO) at 9.07%. This indicates that ZEAL.CO's price experiences larger fluctuations and is considered to be riskier than NOVO-B.CO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| ZEAL.CO | NOVO-B.CO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 48.77% | 9.07% | +39.70% |
Volatility (6M)Calculated over the trailing 6-month period | 58.53% | 40.80% | +17.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 66.35% | 55.40% | +10.95% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.85% | 38.25% | +21.60% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 52.09% | 32.32% | +19.77% |
Financials
ZEAL.CO vs. NOVO-B.CO - Financials Comparison
This section allows you to compare key financial metrics between Zealand Pharma A/S and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities